Payment overview · 2025
General Payments
$2,121.46
139 reported records · 24 companies
Healthcare provider profile · identity verified
Vineeth Kumar, MD
Allopathic & Osteopathic Physicians|Family Medicine · HEATH, TX · NPI 1689108680
Verified facts
What the public records show
CMS Open Payments records show Vineeth Kumar, MD received $2,121.46 in general payments during 2025 across 139 reported records.
ABBVIE INC. accounted for 9.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $199.06 | 9.4% | 21 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $194.26 | 9.2% | 17 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $187.56 | 8.8% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $183.67 | 8.7% | 21 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $178.99 | 8.4% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.43 | 7.6% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $147.48 | 7.0% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $143.74 | 6.8% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $97.72 | 4.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $83.14 | 3.9% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $74.26 | 3.5% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $63.58 | 3.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $63.21 | 3.0% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $56.09 | 2.6% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $52.99 | 2.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.98 | 2.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.39 | 2.1% | 2 | 2025 |
| Avvisto Therapeutics, LLC | Unresolved — no canonical attribution shown | $33.71 | 1.6% | 2 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $23.56 | 1.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.95 | 0.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.06 | 0.9% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.55 | 0.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.19 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.89 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,121.46 | 139 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $187.56 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $183.67 | 21 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $143.74 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $129.48 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $129.48 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $128.63 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $106.93 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $100.91 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $97.72 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $86.96 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $79.05 | 9 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $74.26 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $71.76 | 8 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $70.32 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $63.58 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $63.21 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $60.56 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $60.52 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $58.31 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $56.69 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $56.09 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $52.99 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.49 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $44.39 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $44.37 | 3 | 2025 |
Source payment records
|
|||||
| CYCLOSET Normalized: cycloset |
Drug | Avvisto Therapeutics, LLC | $33.71 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $26.45 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $8.28 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $7.17 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $2.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 40 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 246 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 153 | 51 |
| Lisinopril | Lisinopril | 116 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 35 |
| Metformin Hcl Er | Metformin Hcl | 104 | 39 |
| Losartan Potassium | Losartan Potassium | 101 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 48 |
| Gabapentin | Gabapentin | 98 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 40 |
| Omeprazole | Omeprazole | 89 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 26 |
| Trazodone Hcl | Trazodone Hcl | 87 | 33 |
| Metformin Hcl | Metformin Hcl | 82 | 30 |
| Ozempic | Semaglutide | 76 | 17 |
| Montelukast Sodium | Montelukast Sodium | 75 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 58 | 21 |
| Furosemide | Furosemide | 55 | 33 |
| Meloxicam | Meloxicam | 55 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 18 |
| Alprazolam | Alprazolam | 51 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 23 |
| Azithromycin | Azithromycin | 48 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 15 |
| Carvedilol | Carvedilol | 41 | 15 |
| Eliquis | Apixaban | 40 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 13 |
| Progesterone | Progesterone, Micronized | 38 | 14 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 17 |
| Simvastatin | Simvastatin | 37 | 14 |
| Sertraline Hcl | Sertraline Hcl | 36 | 16 |
| Ezetimibe | Ezetimibe | 34 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 34 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 20 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 19 |
| Celecoxib | Celecoxib | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | 14 |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Climara | Estradiol | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 12 |
| Irbesartan | Irbesartan | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,121.46 · 139 records | ABBVIE INC. | ABRYSVO, AREXVY, Auvelity, Azstarys, BREZTRI, COMIRNATY, CREON, CYCLOSET, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, GEMTESA, JARDIANCE, KEVEYIS, KRYSTEXXA, Kerendia, Korlym, LINZESS, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, PROLIA, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, Rybelsus, SHINGRIX, SPRAVATO, Symbravo, TRINTELLIX, TZIELD, UBRELVY, VRAYLAR, VYNDAMAX, VYNDAQEL, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error